PATENT CLAIM ANALYSIS

Application Number: 16065397
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "387000"]

Abstract:
Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.

Claim (Index 77):
The compound of  claim 1  that is\n 4-(5H-imidazo[1,5-b]isoindol-5-yl)-2,2-dimethyl-cyclobutanol; \n (S)-1-((R)-5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol; \n (R)-1-(5H-imidazo[5,1-a]isoindol-5-yl)cyclohexan-1-ol; \n (4S,5S)-5-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-4-ol; \n ((5R,6S)-5-hydroxy-6-((R)-5H-imidazo[5,1-a]isoindol-5-yl)-5,6,7,8-tetrahydronaphthalene-2-sulfonamide; or \n (4S,5S)-4-hydroxy-5-((R)-5H-imidazo[5,1-a]isoindol-5-yl)-4,5,6,7-tetrahydrobenzo[d]thiazole-2-carboxamide.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.34783
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12666423', '15122863', '14061616', '16472185', '13897927']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8179585231871238
- 35 USC 102 Novelty (BERT): 0.5344500218287337
- Combined Prediction Score: 0.7896076730512849
- Mean Citation Score: 367.118278
- Max Citation Score: 369.48654
- Similarity Product: 295.13153002706764

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test